Antibodies Diggers

Who we are

Pomona Ricerca S.r.l. is a private Italian R&D biotech company engaged to find solutions to important medical needs through the study of human broadly neutralizing antibodies.

Pomona Ricerca’s focus centers on the concept of neutralizing antibodies, as defines by Nobel Prize winner Paul Ehrlich referred as ‘magic bullet’, to use as therapeutic biomolecules. Moreover, the exploration and analysis of neutralizing antibodies by Pomona enable the company to engage in the creation and advancement of cutting-edge epitope-based vaccines utilizing the anti-idiotype response strategy, commonly known as the anti-idiotype vaccine.

The company has currently a strong intellectual property portfolio of internationally granted patents that cover multiple antibody candidates ready to address the clinical development stage.

In particular, Pomona has identified different neutralizing antibodies against hepatitis C virus, influenza virus and JC virus and has recently developed the first anti-idiotypic antibody able to elicit an immune response against HIV-1.

The R&D activity can be divided into two main categories:

cloning, development, and characterization of human broadly neutralizing monoclonal antibodies against pathogens
development of novel vaccine and drug preparations directly derived from the understanding of the immune response and the identification of neutralizing conserved viral epitopes

Pomona Ricerca has developed and still maintains collaboration agreements with Italian, European, South African and US research institutions.

The commercial activity can be divided into two main categories:

distribution of recombinant proteins: Hemagglutinin (HA), Neuraminidase (NA), RSV F protein, SARS-CoV-2 Spike
⁠ ⁠provide support to other companies in the cloning and characterization of monoclonal antibodies against pathogens.